Copy number variants, or CNVs, are deletions or duplications of stretches of DNA that can span anywhere from a few hundred bases to millions of bases and can remove, add, or disrupt entire genes. Unlike single-nucleotide variants, which change a single DNA letter, CNVs reshape the genome’s structural landscape, and when they occur in genes critical to brain development they can have outsized effects on neurodevelopmental and psychiatric outcomes. Several recurrent CNVs, such as deletions at the 22q11.2 locus, have been known for years to dramatically elevate schizophrenia risk, but nearly all of that knowledge was built on cohorts of predominantly European descent. Whether the same structural variants, or entirely different ones, contribute to schizophrenia in East Asian populations, which make up a substantial fraction of the world’s population and carry distinct patterns of genomic variation, remained an open and important question.

The new study addressed that question by assembling and analyzing genome-wide data from individuals of East Asian ancestry, comparing the burden of rare copy number variants in people diagnosed with schizophrenia against unaffected controls. The analytic strategy relied on high-quality genotyping arrays and sequencing-based calls that allow researchers to detect deletions and duplications across the genome, followed by careful filtering to remove likely artifacts and annotation of each variant against gene content, known disease loci, and measures of a gene’s intolerance to loss-of-function variation. Burden tests, which ask whether cases collectively carry more large, rare, gene-disrupting CNVs than controls, form the statistical backbone of this kind of work, and the study applied them with the sample sizes needed to detect effects that individual variants alone would be too rare to reveal.

The results confirmed that the fundamental burden signal holds across ancestries. People with schizophrenia in East Asian cohorts carried a significant excess of rare CNVs, particularly those that are large, that remove or duplicate many genes, and that overlap genes previously implicated in neurodevelopmental disorders. This is precisely the pattern observed in European studies, and its replication in an East Asian setting carries real weight: it suggests that the structural-variant contribution to schizophrenia is not an artifact of any one population’s genomic history or ascertainment, but a genuine and broadly shared feature of the disorder’s genetic architecture. For clinicians and researchers in East Asia, it also validates the use of CNV screening in psychiatric care and research contexts far beyond the populations in which those tools were originally developed.

Beyond confirming the overall burden, the analyses pinpointed specific rare copy number variants associated with schizophrenia in East Asian populations, contributing new population-specific resolution to a catalog of risk loci that has been heavily Eurocentric. Some of these signals overlap with CNV loci already known from European studies, reinforcing their status as reproducible schizophrenia risk factors, while the East Asian data add power and detail to their characterization. Because the frequencies of specific structural variants differ across populations, owing to drift, demographic history, and selection, mapping them in East Asian genomes is essential for building risk models and genetic counseling frameworks that actually fit the populations being served.

The most ambitious component of the work, however, was its meta-analysis. By combining East Asian results with those from large European ancestry studies, the investigators boosted statistical power well beyond what either cohort could achieve alone and searched for CNV loci associated with schizophrenia across ancestries. This trans-ancestry approach identified additional risk loci that no single population had the numbers to confirm on its own. The logic is straightforward: if a rare variant’s effect is genuine, pooling evidence across populations with different linkage disequilibrium patterns and different variant spectrums reduces confounding and sharpens the signal. Structural variants, which are often individually very rare and recently arisen, benefit especially from this strategy because their pathogenicity is less dependent on population-specific genetic background than that of common variants.

A striking unifying theme emerged from the annotation of these loci. The genes disrupted by the associated CNVs were significantly enriched for those that are intolerant to loss-of-function variants, meaning that in population sequencing databases, damaging mutations in these genes appear far less often than expected by chance. Genes under strong purifying selection in this way are typically those in which gene dosage matters: losing one copy, or gaining an extra one, perturbs biological systems enough to be selected against. In the brain, dosage-sensitive genes cluster in pathways governing synaptic function, neuronal development, and signaling. The finding that schizophrenia-associated CNVs converge on loss-of-function intolerant genes ties the disorder’s structural-variant risk to the same dosage-sensitive neurodevelopmental biology implicated by de novo mutations in autism, developmental delay, and congenital anomalies, reinforcing a picture of overlapping genetic mechanisms across neuropsychiatric conditions.

The implications run in several directions at once. Scientifically, the study helps close a long-standing gap in psychiatric genetics, demonstrating that rare structural variation is a universal contributor to schizophrenia risk and supplying East Asian-specific loci that will refine global catalogs of disease genes. Methodologically, it shows the value of building genomic resources in understudied populations and then integrating them through meta-analysis rather than extrapolating from European data. Clinically, dosage-sensitive CNV loci identified across ancestries could inform the emerging practice of returning secondary findings to psychiatric patients, since carriers of known pathogenic CNVs may benefit from surveillance for associated medical comorbidities. And for drug discovery, each new risk locus is a pointer toward biology, with dosage-sensitive genes offering mechanistic hypotheses about synaptic and developmental processes that go awry in psychosis.

The study also arrives amid a broader recalibration of how the field thinks about the genetics of schizophrenia. Genome-wide association studies have catalogued hundreds of common variant loci that collectively explain a large share of heritability but individually contribute tiny effects, while rare, high-impact variants such as large CNVs explain a smaller but more mechanistically tractable slice of risk. Rare structural variants, particularly those spanning multiple loss-of-function intolerant genes, are among the strongest known genetic risk factors for the disorder, and the demonstration that this risk architecture replicates in East Asian populations strengthens confidence that findings from these variants will translate broadly. The remaining challenges are considerable: sample sizes for rare variant discovery in non-European populations still lag far behind those in Europe, detection and comparison of CNVs across platforms and ancestries remains technically demanding, and translating locus discovery into biological understanding requires functional work well beyond association statistics.

Still, the trajectory is clear. Schizophrenia genetics has moved from single candidate genes to genome-wide surveys, from one continent to many, and from catalogs of associations to mechanistic principles such as dosage sensitivity and loss-of-function intolerance that bind risk loci into coherent biological stories. By showing that East Asian populations carry the same excess of rare, gene-disrupting copy number variants, and by using trans-ancestry pooling to surface additional risk loci enriched in genes that evolution refuses to let break, this work takes a significant step toward a genetic account of schizophrenia that genuinely fits the global population it affects. It is a reminder that the path to understanding a universal human illness must, by necessity, run through all of humanity’s genomes.

Subject of Research: Rare copy number variants associated with schizophrenia in East Asian populations

Article Title: Contribution of copy number variants to schizophrenia in East Asian populations

Article References: Chen, Y., Feng, Q., Lam, M., Yu, M., Sun, Y., Huai, C., Jana, B., Fu, J., Liao, C., Ye, R., Kim, S., Tubbs, J. D., Shanta, O., Thiruvahindrapuram, B., Jen, Y., Zhao, G., Wang, J., Stanley Global Asia Initiatives, Schwab, S. G., … Huang, H. (2026). Contribution of copy number variants to schizophrenia in East Asian populations. Nature Genetics. https://doi.org/10.1038/s41588-026-02732-6

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02732-6

Keywords: schizophrenia, copy number variants, East Asian populations, genomics, rare variants, meta-analysis, genetic risk loci, loss-of-function intolerance, Nature Genetics, psychiatric genetics, population genetics, neurodevelopmental genes